Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,17502775,trough serum concentration,The dose of carbamazepine was titrated to produce a trough serum concentration within the range of 8 to 12 mg/L.,Pharmacokinetics of aripiprazole and concomitant carbamazepine. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17502775/),[mg] / [l],8 to 12,3752,DB01238,Aripiprazole
less,32726002,Relative attenuation ratios,"Relative attenuation ratios were less than 1, indicating a slower central versus peripheral attenuation, across the time points for all antipsychotic types and doses with only a few exceptions.",Dissociation in Pharmacokinetic Attenuation Between Central Dopamine D2 Receptor Occupancy and Peripheral Blood Concentration of Antipsychotics: A Systematic Review. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32726002/),,1,3875,DB01238,Aripiprazole
,25586294,plasma concentration,"In clinical studies, when patients initiated AOM 400 with concomitant oral aripiprazole (10-15 mg/d based on stabilized dose) or continued their previous antipsychotic for ≤14 days, mean aripiprazole plasma concentration after 4 weeks (93 to 112 ng/mL) was in range of the therapeutic window established for aripiprazole (94.0-534.0 ng/mL).",Initiation of aripiprazole once-monthly in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586294/),[ng] / [ml],93 to 112,5610,DB01238,Aripiprazole
,25586294,plasma concentration,"In clinical studies, when patients initiated AOM 400 with concomitant oral aripiprazole (10-15 mg/d based on stabilized dose) or continued their previous antipsychotic for ≤14 days, mean aripiprazole plasma concentration after 4 weeks (93 to 112 ng/mL) was in range of the therapeutic window established for aripiprazole (94.0-534.0 ng/mL).",Initiation of aripiprazole once-monthly in patients with schizophrenia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25586294/),[ng] / [m],94.0-534.0,5611,DB01238,Aripiprazole
,22989976,polydispersion index (PI),The resultant APZ nanosuspensions showed a mean particle size of 350 nm with polydispersion index (PI) value of 0.20.,Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),,0,18859,DB01238,Aripiprazole
,22989976,relative bioavailability,"APZ nanosuspensions got maximum absorption rate and extent comparing with APZ commercial tablet and suspensions with relative bioavailability of 123.43 ± 12.98% and 171.41 ± 14.62%, respectively.",Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),%,123.43,18860,DB01238,Aripiprazole
,22989976,relative bioavailability,"APZ nanosuspensions got maximum absorption rate and extent comparing with APZ commercial tablet and suspensions with relative bioavailability of 123.43 ± 12.98% and 171.41 ± 14.62%, respectively.",Enhanced dissolution and oral bioavailability of aripiprazole nanosuspensions prepared by nanoprecipitation/homogenization based on acid-base neutralization. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22989976/),%,171.41,18861,DB01238,Aripiprazole
,18381901,E(max) (EC(50)),The values for serum concentration predicted to provide 50% of E(max) (EC(50)) were in the range of 5-10 ng/ml in all brain regions.,Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]fallypride PET study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18381901/),[ng] / [ml],5-10,22652,DB01238,Aripiprazole
,30259403,relative bioavailability,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),,66,28773,DB01238,Aripiprazole
,30259403,AUC0-10h,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),[h·ng] / [ml],16.38,28774,DB01238,Aripiprazole
,30259403,AUC0-10h,"The obtained pharmacokinetic results showed that the relative bioavailability for orally administered ARP-loaded silicosan particles (SC-2-CTAB) was 66% higher relative to the oral suspension (AUC0-10h was 16.38 ± 3.21 and 27.23 ± 2.35 ng.h/mL for drug powder and SC-2-CTAB formulation, respectively).","Bioavailability Enhancement of Aripiprazole Via Silicosan Particles: Preparation, Characterization and In vivo Evaluation. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30259403/),[h·ng] / [ml],27.23,28775,DB01238,Aripiprazole
,27861318,plasma trough concentration,"It has been suggested that a plasma trough concentration of aripiprazole plus its active metabolite, dehydroaripiprazole of 225 ng/mL is a threshold for a good therapeutic response in the treatment of acutely exacerbated patients with schizophrenia.",Prediction of an Optimal Dose of Aripiprazole in the Treatment of Schizophrenia From Plasma Concentrations of Aripiprazole Plus Its Active Metabolite Dehydroaripiprazole at Week 1. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27861318/),[ng] / [ml],225,52271,DB01238,Aripiprazole
,15897016,flow rate,"Separation was by Nova-pak phenyl column; flow rate, 1.0 ml/min; mobile phase, acetonitrile-methanol-20 mM sodium sulfate-acetic acid (27:25:48:1, v/v/v/v); UV detection at 254 nm.",High performance liquid chromatographic methods for the determination of aripiprazole with ultraviolet detection in rat plasma and brain: application to the pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15897016/),[ml] / [min],1.0,68956,DB01238,Aripiprazole
,31308935,maximum plasma aripiprazole concentrations,Mean maximum plasma aripiprazole concentrations were 196.1 ng/ml (deltoid) and 175.0 ng/ml (gluteal).,Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31308935/),[ng] / [ml],196.1,72444,DB01238,Aripiprazole
,31308935,maximum plasma aripiprazole concentrations,Mean maximum plasma aripiprazole concentrations were 196.1 ng/ml (deltoid) and 175.0 ng/ml (gluteal).,Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31308935/),[ng] / [ml],175.0,72445,DB01238,Aripiprazole
,31308935,AUC∞,"Exposure to aripiprazole was similar, with mean AUC∞ values of 6591 day × ng/ml for deltoid and 6437 day × ng/ml for gluteal.",Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31308935/),[d·ng] / [ml],6591,72446,DB01238,Aripiprazole
,31308935,AUC∞,"Exposure to aripiprazole was similar, with mean AUC∞ values of 6591 day × ng/ml for deltoid and 6437 day × ng/ml for gluteal.",Pharmacokinetics and safety of deltoid or gluteal injection of aripiprazole lauroxil NanoCrystal® Dispersion used for initiation of the long-acting antipsychotic aripiprazole lauroxil. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31308935/),[d·ng] / [ml],6437,72447,DB01238,Aripiprazole
,14747427,elimination half-life,"In Study 1, mean elimination half-life ranged from 47 to 68 hours with aripiprazole, with apparent systemic clearance (CL/F) of approximately 3.45 L/h.","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),h,47 to 68,80081,DB01238,Aripiprazole
,14747427,apparent systemic clearance (CL/F),"In Study 1, mean elimination half-life ranged from 47 to 68 hours with aripiprazole, with apparent systemic clearance (CL/F) of approximately 3.45 L/h.","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),[l] / [h],3.45,80082,DB01238,Aripiprazole
,14747427,elimination half-life,"In Study 2, mean elimination half-life was 59 hours (CL/F approximately 4.0 L/h).","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),h,59,80083,DB01238,Aripiprazole
,14747427,CL/F,"In Study 2, mean elimination half-life was 59 hours (CL/F approximately 4.0 L/h).","Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14747427/),[l] / [h],4.0,80084,DB01238,Aripiprazole
,23463771,flow rate,"Chromatographic separation was achieved on a Phenomenex C18 (4.6 × 50 mm, 5 µm) column with 0.1% formic acid-acetonitrile (10:90, v/v) as the mobile phase with flow rate of 0.6 mL/min.",Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463771/),[ml] / [min],0.6,89530,DB01238,Aripiprazole
,23463771,recovery,Mean recovery was in the range of 69.94-75.62% for both analytes and internal standards.,Liquid chromatography-tandem mass spectrometry method for simultaneous quantification of urapidil and aripiprazole in human plasma and its application to human pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23463771/),%,69.94-75.62,89531,DB01238,Aripiprazole
,23890595,Completion rates,"Completion rates were 36.4% (n=4/11), 50.0% (n=8/16) and 71.4% (n=10/14) for the 200mg, 300 mg and 400mg groups, respectively.","Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23890595/),%,36,94478,DB01238,Aripiprazole
,33515583,maximum rate of permeation co-efficient,The improved in vitro release profile of the formulation was in agreement to enhanced ex vivo permeation through sheep mucous membranes with a maximum rate of permeation co-efficient (62.87 cm h-1 × 103) and flux (31.43 μg cm-2.h-1).,Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[103·cm] / [h],62.87,102752,DB01238,Aripiprazole
,33515583,flux,The improved in vitro release profile of the formulation was in agreement to enhanced ex vivo permeation through sheep mucous membranes with a maximum rate of permeation co-efficient (62.87 cm h-1 × 103) and flux (31.43 μg cm-2.h-1).,Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [(cm)^2·h],31.43,102753,DB01238,Aripiprazole
,33515583,maximum concentration of drug in the brain (Cmax),"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],15.19,102754,DB01238,Aripiprazole
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),h,1,102755,DB01238,Aripiprazole
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],10.57,102756,DB01238,Aripiprazole
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),[μg] / [ml],2.52,102757,DB01238,Aripiprazole
,33515583,Tmax,"The pharmacokinetic profile following single-dose administration showed the maximum concentration of drug in the brain (Cmax) of 15.19 ± 2.51 μg mL-1 and Tmax of 1 h in animals with ARP-MNE as compared to 10.57 ± 1.88 μg mL-1 and 1 h, and 2.52 ± 0.38 μg mL-1 and 3 h upon intranasal and intravenous administration of ARP-NE, respectively.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),h,3,102758,DB01238,Aripiprazole
,33515583,% drug targeting efficiency,"Further, higher values of % drug targeting efficiency (96.9%) and % drug targeting potential (89.73%) of ARP-MNE through intranasal administration were investigated.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),%,96.9,102759,DB01238,Aripiprazole
,33515583,% drug targeting potential,"Further, higher values of % drug targeting efficiency (96.9%) and % drug targeting potential (89.73%) of ARP-MNE through intranasal administration were investigated.",Antipsychotic Potential and Safety Profile of TPGS-Based Mucoadhesive Aripiprazole Nanoemulsion: Development and Optimization for Nose-To-Brain Delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33515583/),%,89.73,102760,DB01238,Aripiprazole
,22767645,flow rate,"The eluted samples were chromatographed on a Grace Smart RP 18 4.6 × 100 mm, 3 µ column by using a 95:5 v/v mixture of methanol and ammonium acetate buffer (30 mM, pH 5.0 ± 0.05) as a gradient mobile phase at a flow rate of 0.6 mL/min, and analyzed by mass spectrometry in the multiple reaction monitoring mode using the [M + H](+) ions m/z 448.03 → 285.14 for aripiprazole and m/z 308.13 → 235.25 for the internal standard (zolpidem tartrate), respectively.",Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),[ml] / [min],0.6,123302,DB01238,Aripiprazole
,22767645,Extraction recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,75.56-79.57,123303,DB01238,Aripiprazole
,22767645,recovery,Extraction recovery of aripiprazole from plasma was in the range 75.56-79.57%; mean recovery was 77.35%.,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),%,77.35,123304,DB01238,Aripiprazole
,22767645,T(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,4.00,123305,DB01238,Aripiprazole
,22767645,C(max),The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,55.16,123306,DB01238,Aripiprazole
,22767645,AUC,The main pharmacokinetic parameters were T(max) = (4.00 ± 2.336) C(max) = (55.16 ± 13.490) and AUC = (1846.28 ± 484.686).,Development and validation of an LC-ESI-MS method for quantitative determination of aripiprazole in human plasma and an application to pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22767645/),,1846.28,123307,DB01238,Aripiprazole
greater,23510852,extraction recovery,"The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively.",SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23510852/),%,96,126558,DB01238,Aripiprazole
,23510852,extraction recovery,"The mean extraction recovery was greater than 96% across QC levels, while intra- and inter batch accuracy and precision (% CV) values ranged from 97.4 to 101.9% and from 1.20 to 3.72% respectively.",SPE-UPLC-MS/MS method for sensitive and rapid determination of aripiprazole in human plasma to support a bioequivalence study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23510852/),%,1,126559,DB01238,Aripiprazole
,19032724,absorption rate constant,The absorption rate constant was fixed to 1.06 h(-1).,"Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032724/),1/[h],1.06,136567,DB01238,Aripiprazole
,19032724,apparent distribution volume,The typical value of apparent distribution volume of aripiprazole was estimated to be 192 l.,"Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19032724/),l,192,136568,DB01238,Aripiprazole
,27207059,PS,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),nm,199.2,137549,DB01238,Aripiprazole
,27207059,zeta potential,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,-,137550,DB01238,Aripiprazole
,27207059,zeta potential,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,21.4,137551,DB01238,Aripiprazole
,27207059,%EE,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),m,21.4,137552,DB01238,Aripiprazole
,27207059,%EE,"PS, zeta potential and %EE of optimized APNPs were found to be 199.2±5.65nm, -21.4±4.6mV and 69.2±2.34% respectively.",Aripiprazole loaded poly(caprolactone) nanoparticles: Optimization and in vivo pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207059/),%,69.2,137553,DB01238,Aripiprazole
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],125.8,148220,DB01238,Aripiprazole
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],131.1,148221,DB01238,Aripiprazole
,28597226,"C avg,ss","The mean C avg,ss values were 125.8 ng/ml, 131.1 ng/ml, and 140.7 ng/ml for the 441 mg q4wk, 882 mg q6wk, and 1064 mg q8wk doses, respectively.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),[ng] / [ml],140.7,148222,DB01238,Aripiprazole
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,53.9,148223,DB01238,Aripiprazole
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,55.1,148224,DB01238,Aripiprazole
,28597226,elimination half-life,"The mean elimination half-life of aripiprazole following the last dose was 53.9 days for the 1064 mg dose, 55.1 days for the 882 mg dose, and 57.2 days for the 441 mg dose.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,57.2,148225,DB01238,Aripiprazole
,28597226,duration of absorption,"The duration of absorption of aripiprazole was estimated as 43 days (95% confidence interval [CI] 42-45 days), which was preceded by a 3.2-day lag time (95% CI 3.0-3.5 days) for a total duration of input into the systemic circulation of 46 days following intramuscular administration of AL.",Pharmacokinetic Profile of a 2-Month Dose Regimen of Aripiprazole Lauroxil: A Phase I Study and a Population Pharmacokinetic Model. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28597226/),d,43,148226,DB01238,Aripiprazole
,23760876,maximum concentration,"Mean maximum concentration, area under the curve from zero to infinity and half-life of the pitolisant were found to be 3.4 ± 1.7 ng/mL, 5 ± 4 ng h/mL and 1.9 ± 0.3 h, respectively, after a 3 mg/kg oral dose.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),[ng] / [ml],3.4,150846,DB01238,Aripiprazole
,23760876,area under the curve from zero to infinity,"Mean maximum concentration, area under the curve from zero to infinity and half-life of the pitolisant were found to be 3.4 ± 1.7 ng/mL, 5 ± 4 ng h/mL and 1.9 ± 0.3 h, respectively, after a 3 mg/kg oral dose.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),[h·ng] / [ml],5,150847,DB01238,Aripiprazole
,23760876,half-life,"Mean maximum concentration, area under the curve from zero to infinity and half-life of the pitolisant were found to be 3.4 ± 1.7 ng/mL, 5 ± 4 ng h/mL and 1.9 ± 0.3 h, respectively, after a 3 mg/kg oral dose.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),h,1.9,150848,DB01238,Aripiprazole
,23760876,concentrations,"The mean calculated concentrations in the brain were found to be 38, 60 and 52 ng/g at 0.5, 1 and 2 h, respectively.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),[ng] / [g],38,150849,DB01238,Aripiprazole
,23760876,concentrations,"The mean calculated concentrations in the brain were found to be 38, 60 and 52 ng/g at 0.5, 1 and 2 h, respectively.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),[ng] / [g],60,150850,DB01238,Aripiprazole
,23760876,concentrations,"The mean calculated concentrations in the brain were found to be 38, 60 and 52 ng/g at 0.5, 1 and 2 h, respectively.",LC-MS/MS method for the determination of pitolisant: application to rat pharmacokinetic and brain penetration studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23760876/),[ng] / [g],52,150851,DB01238,Aripiprazole
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],26,159154,DB01238,Aripiprazole
,19132712,maximum plasma concentration,Geometric mean (GM) values for lamotrigine maximum plasma concentration were similar for lamotrigine alone (26 ng/mL) and with co-administered aripiprazole (23 ng/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [ml],23,159155,DB01238,Aripiprazole
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],434,159156,DB01238,Aripiprazole
,19132712,area under the concentration-time curve (AUCtau),GM values for plasma lamotrigine area under the concentration-time curve (AUCtau) were comparable for lamotrigine alone (434 ng/h/mL) and with co-administered aripiprazole (394 ng/h/mL).,A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),[ng] / [h·ml],394,159157,DB01238,Aripiprazole
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,1.98,159158,DB01238,Aripiprazole
,19132712,T(max),"Median T(max) of lamotrigine alone and combined with aripiprazole was 1.98 and 0.77 h, respectively.",A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19132712/),h,0.77,159159,DB01238,Aripiprazole
,22406103,elution at flow rate,"The analysis was carried out on an ACQUITY UPLC™ BEH HILIC column (1.7 μm, 2.1 mm×50 mm) with isocratic elution at flow rate of 0.2 mL/min using 10mM ammonium formate in 0.1% formic acid and acetonitrile (10:90) as the mobile phase.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),[ml] / [min],0.2,161605,DB01238,Aripiprazole
,22406103,run time,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,4,161606,DB01238,Aripiprazole
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.6,161607,DB01238,Aripiprazole
,22406103,retention times,"The validated analytical method resulted in a run time of 4 min and the retention times observed were 2.6±0.1 and 2.1±0.1 min for CM156 and the IS, respectively.","Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),min,2.1,161608,DB01238,Aripiprazole
,22406103,recovery,The mean recovery of CM156 from plasma was 96.8%.,"Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22406103/),%,96.8,161609,DB01238,Aripiprazole
,22943745,T(max),"Furthermore, the addition of aripiprazole did not change the median T(max) of lithium or valproate (4 h).",Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22943745/),h,4,162135,DB01238,Aripiprazole
,27506082,AUC(28d),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[h·μg] / [ml],165,175867,DB01238,Aripiprazole
,27506082,C(max),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[ng] / [ml],331,175868,DB01238,Aripiprazole
,27506082,C(min),"After the fifth AOM 400 injection, mean aripiprazole AUC(28d), C(max) and C(min) were 165 μg x h/ml, 331 ng/ml and 201 ng/ml, respectively, which were similar to previously published pharmacokinetic parameters after the fifth gluteal injection of AOM 400.","[Pharmacokinetics and safety of aripiprazole long-acting injection, following multiple deltoid administrations in schizophrenia patients in Japan]. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27506082/),[ng] / [ml],201,175869,DB01238,Aripiprazole
,21049519,total time,"Peaks were detected with an UV detector set at a wavelength of 254 nm, and the total time for chromatographic separation was ∼20 min.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),min,∼20,180267,DB01238,Aripiprazole
,21049519,absolute recoveries,"Mean absolute recoveries were 74.0 and 74.7% for aripiprazole and dehydroaripiprazole, respectively.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),%,74.0,180268,DB01238,Aripiprazole
,21049519,absolute recoveries,"Mean absolute recoveries were 74.0 and 74.7% for aripiprazole and dehydroaripiprazole, respectively.",A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),%,74.7,180269,DB01238,Aripiprazole
,21049519,limits of detection,The validated concentration ranges for this method were 1-500 ng/mL and the limits of detection were 0.5 ng/mL for both aripiprazole and dehydroaripiprazole.,A sensitive column-switching HPLC method for aripiprazole and dehydroaripiprazole and its application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21049519/),[ng] / [ml],0.5,180270,DB01238,Aripiprazole
,29510329,flow rate,"Chromatographic separation was performed on an Agilent Eclipse XDB-CN column (100 × 2.1 mm i.d., 3.5 μm) using the mobile phase of water and acetonitrile (25:75, v/v) containing 0.1% formic acid with a flow rate of 0.5 mL/min.",LC-MS/MS method for the determination of the prodrug aripiprazole lauroxil and its three metabolites in plasma and its application to in vitro biotransformation and animal pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29510329/),[ml] / [min],0.5,186314,DB01238,Aripiprazole
,33400035,Tmax,Oral bioavailability studies in Sprague-Dawley rats confirmed quicker and greater extent of absorption with solid SMEDDS as evident from the significant reduction in Tmax in case of solid SMEDDS (0.83 ± 0.12 h) as compared with commercial tablet (3.33 ± 0.94 h).,pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400035/),h,0.83,188631,DB01238,Aripiprazole
,33400035,Tmax,Oral bioavailability studies in Sprague-Dawley rats confirmed quicker and greater extent of absorption with solid SMEDDS as evident from the significant reduction in Tmax in case of solid SMEDDS (0.83 ± 0.12 h) as compared with commercial tablet (3.33 ± 0.94 h).,pH-Independent Dissolution and Enhanced Oral Bioavailability of Aripiprazole-Loaded Solid Self-microemulsifying Drug Delivery System. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33400035/),h,3.33,188632,DB01238,Aripiprazole
,14686220,oral availability,The oral availability is 87%.,Aripiprazole. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),%,87,189040,DB01238,Aripiprazole
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,75,189041,DB01238,Aripiprazole
,14686220,elimination half-life,The mean elimination half-life is about 75 hours for aripiprazole and 94 hours for its active metabolite.,Aripiprazole. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14686220/),h,94,189042,DB01238,Aripiprazole
,28204607,time to maximum plasma concentration,"After single-dose administration, aripiprazole exposure (area under the concentration-time curve) was similar between deltoid and gluteal administrations, whereas median time to maximum plasma concentration was shorter (7.1 [deltoid] vs 24.1 days [gluteal]) and maximum concentration was 31% higher after deltoid administration.","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,7.1,208352,DB01238,Aripiprazole
,28204607,time to maximum plasma concentration,"After single-dose administration, aripiprazole exposure (area under the concentration-time curve) was similar between deltoid and gluteal administrations, whereas median time to maximum plasma concentration was shorter (7.1 [deltoid] vs 24.1 days [gluteal]) and maximum concentration was 31% higher after deltoid administration.","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,24.1,208353,DB01238,Aripiprazole
,28204607,time to maximum plasma concentration,"In the multiple-dose study, median time to maximum plasma concentration for deltoid administration was shorter (3.95 vs 7.1 days), whereas aripiprazole mean trough concentrations, maximum concentration, and area under the concentration-time curve were comparable between deltoid and gluteal muscles (historical data comparison).","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,3.95,208354,DB01238,Aripiprazole
,28204607,time to maximum plasma concentration,"In the multiple-dose study, median time to maximum plasma concentration for deltoid administration was shorter (3.95 vs 7.1 days), whereas aripiprazole mean trough concentrations, maximum concentration, and area under the concentration-time curve were comparable between deltoid and gluteal muscles (historical data comparison).","Aripiprazole Once-Monthly 400 mg: Comparison of Pharmacokinetics, Tolerability, and Safety of Deltoid Versus Gluteal Administration. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28204607/),d,7.1,208355,DB01238,Aripiprazole
,25266547,Tmax,"The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days).","Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25266547/),d,44-50,208506,DB01238,Aripiprazole
,25266547,t1/2,"The PK of aripiprazole following aripiprazole lauroxil was characterized by a steady rise in plasma concentrations (Tmax 44-50 days), a broad peak, and prolonged exposure attributable to the dissolution of aripiprazole lauroxil and formation rate-limited elimination of aripiprazole (t1/2=15.4-19.2 days).","Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25266547/),d,15.4-19.2,208507,DB01238,Aripiprazole
,18611062,CL(R),The mean CL(R) of aripiprazole was negligible (0.04 mL/h/kg in controls and 0.19 mL/h/kg in patients with severe hepatic impairment).,Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611062/),[ml] / [h·kg],0.04,210387,DB01238,Aripiprazole
,18611062,CL(R),The mean CL(R) of aripiprazole was negligible (0.04 mL/h/kg in controls and 0.19 mL/h/kg in patients with severe hepatic impairment).,Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole. ,CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18611062/),[ml] / [h·kg],0.19,210388,DB01238,Aripiprazole
,29324280,flow rate,"A combination of ammonium formate (5 mM)-acetonitrile (pH 4.0; 65:35, v/v) was used as mobile phase and the chromatogram was run under gradient conditions at a flow rate of 0.6 ml/min.",Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29324280/),[ml] / [min],0.6,216339,DB01238,Aripiprazole
,29324280,total run time,"Run time lasted 5 min, followed by a re-equilibration time of 3 min, to give a total run time of 8 min.",Effective phospholipids removing microelution-solid phase extraction LC-MS/MS method for simultaneous plasma quantification of aripiprazole and dehydro-aripiprazole: Application to human pharmacokinetic studies. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29324280/),min,8,216340,DB01238,Aripiprazole
,24678101,t1/2,"After multiple oral doses (10 mg g12h), the mean (SD) t1/2, Css max, Tmax, MRT, V/F, and CL/F were 62.2 (9.0) hours, 557.3 (135.5) ng/mL, 2.6 (1.1) hours, 84.5 (11.2) hours, 173 (48) L, and 1.9 (0.5) L/h, respectively.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,62.2,228250,DB01238,Aripiprazole
,24678101,CL/F,"After multiple oral doses (10 mg g12h), the mean (SD) t1/2, Css max, Tmax, MRT, V/F, and CL/F were 62.2 (9.0) hours, 557.3 (135.5) ng/mL, 2.6 (1.1) hours, 84.5 (11.2) hours, 173 (48) L, and 1.9 (0.5) L/h, respectively.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],1.9,228251,DB01238,Aripiprazole
,24678101,t/12,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,62.2,228252,DB01238,Aripiprazole
,24678101,t/12,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),h,68.1,228253,DB01238,Aripiprazole
,24678101,Css max,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[ng] / [ml],557.3,228254,DB01238,Aripiprazole
,24678101,Css max,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[ng] / [ml],393,228255,DB01238,Aripiprazole
,24678101,V/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),l,173,228256,DB01238,Aripiprazole
,24678101,V/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),l,196,228257,DB01238,Aripiprazole
,24678101,CL/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],1.9,228258,DB01238,Aripiprazole
,24678101,CL/F,"In Chinese patients, the t/12 values were numerically similar (62.2 [9.0] vs 68.1 [22.9] hours); Css max values were numerically higher (557.3 [135.5] vs 393 [181 ] ng/mL); and V/F and CL/F values were numerically lower (V/F: 173 [48] vs 196 [66] L; CL/F: 1.9 [0.5] vs 3.4 [1.6] L/h) compared with healthy white male volunteers.","Steady-state pharmacokinetic properties of aripiprazole 10 mg PO g12h in Han Chinese adults with schizophrenia: A prospective, open-label, pilot study. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24678101/),[l] / [h],3.4,228259,DB01238,Aripiprazole
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],6.771,228606,DB01238,Aripiprazole
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],87.87,228607,DB01238,Aripiprazole
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],45.11,228608,DB01238,Aripiprazole
,26391142,IC50,"On the other hand, resveratrol showed inhibitory effect on CYP3A4*1, CYP2D6*1, human and rat microsomes, the IC50 of resveratrol was 6.771, 87.87, 45.11 and 35.59 μmol l(-1), respectively.",The effect of resveratrol on pharmacokinetics of aripiprazole in vivo and in vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26391142/),[μM] / [l],35.59,228609,DB01238,Aripiprazole
,18563956,absolute bioavailability,"In study 1, the geometric mean values for the absolute bioavailability of aripiprazole following oral and intramuscular administration were 0.85 and 0.98, respectively.","Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563956/),,0.85,231304,DB01238,Aripiprazole
,18563956,absolute bioavailability,"In study 1, the geometric mean values for the absolute bioavailability of aripiprazole following oral and intramuscular administration were 0.85 and 0.98, respectively.","Pharmacokinetics and tolerability of intramuscular, oral and intravenous aripiprazole in healthy subjects and in patients with schizophrenia. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18563956/),,0.98,231305,DB01238,Aripiprazole
better,19070586,recoveries,The average recoveries in plasma samples both were better than 85%.,Development of an LC-MS/MS method for the simultaneous quantification of aripiprazole and dehydroaripiprazole in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19070586/),%,85,233288,DB01238,Aripiprazole
,17965519,C(max),"Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),[ng] / [ml],31.0,252106,DB01238,Aripiprazole
,17965519,t(max),"Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,3.6,252107,DB01238,Aripiprazole
,17965519,"t(1/2, z) (terminal phase half life)","Following a single oral 6 mg dose, the mean C(max), t(max), and t(1/2, z) (terminal phase half life) of aripiprazole were 31.0 ng/mL, 3.6 hr, and 61.0 hr, respectively.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,61.0,252108,DB01238,Aripiprazole
,17965519,"t(1/2, z)","The t(1/2, z) in CYP2D6 IM subjects (75.2 hr) was significantly (p<0.01) longer than that in CYP2D6 EM subjects (45.8 hr), and the systemic clearance of IM subjects was approximately 60% that of EM subjects.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,75.2,252109,DB01238,Aripiprazole
,17965519,"t(1/2, z)","The t(1/2, z) in CYP2D6 IM subjects (75.2 hr) was significantly (p<0.01) longer than that in CYP2D6 EM subjects (45.8 hr), and the systemic clearance of IM subjects was approximately 60% that of EM subjects.","Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17965519/),h,45.8,252110,DB01238,Aripiprazole
,17978491,absorption lag time (ALAG),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),h,0.805,267522,DB01238,Aripiprazole
,17978491,absorption rate constant (KA),"The mean values of the absorption lag time (ALAG) and absorption rate constant (KA) were estimated to be 0.805 h and 2.65 h(-1), respectively.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),1/[h],2.65,267523,DB01238,Aripiprazole
,17978491,volume of the central (V(1)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],3.84,267524,DB01238,Aripiprazole
,17978491,peripheral (V(2)/F,"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,V2-Q64,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [kg],1.54,267525,DB01238,Aripiprazole
,17978491,inter-compartment clearance (Q/F),"The mean volume of the central (V(1)/F) and peripheral (V(2)/F) compartment was 3.84 and 1.54 l/kg, respectively, and the mean value of inter-compartment clearance (Q/F) was 0.168 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CL12-Q30,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.168,267526,DB01238,Aripiprazole
,17978491,Oral clearance (CL/F),"Oral clearance (CL/F) was estimated to be 0.0645 l/h/kg in the group with CYP2D6*1/*1, *1/*2 and *2/*2.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0645,267527,DB01238,Aripiprazole
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0135,267528,DB01238,Aripiprazole
,17978491,CL/F,"The decrease in CL/F was estimated to be 0.0135 l/h/kg in the group with CYP2D6*1/*5, *1/*10, *2/*5, *2/*10, and *2/*41, and 0.0293 l/h/kg in the group with CYP2D6*5/*10, *10/*10, and *41/*41.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0293,267529,DB01238,Aripiprazole
,17978491,CL/F,"The plasma concentration of aripiprazole was increased by coadministration of itraconazole, and the decrease in CL/F was estimated to be 0.0181 l/h/kg.",Nonlinear mixed effects model analysis of the pharmacokinetics of aripiprazole in healthy Japanese males. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17978491/),[l] / [h·kg],0.0181,267530,DB01238,Aripiprazole
